BLINCYTO
Q2 2026 sales rose 23% to $472 million; subcutaneous studies are paused under an FDA partial clinical hold.
The numbers
BLINCYTO product sales$472 millionQ2 2026 · up 23% year over year · source ↗
What it is
Bispecific T-cell engager for acute lymphoblastic leukemia, the first BiTE therapy Amgen sold. Amgen is developing a subcutaneous version, but two Phase 2 studies have paused enrollment.
Why it matters to the stock. BLINCYTO is a steady oncology seller. The FDA clinical hold on the subcutaneous program affects Amgen's plan to extend the drug to more patients.
News
No stories tagged to this project yet.